Theriva Biologics Inc - ערך חשבונאי למניה TOVX

The development of VCN-01 oncolytic adenoviruses for pancreatic therapy by Theriva Biologics, Inc. (TOVX) is currently in the active monitoring stage. A team of virologists and oncologists is focused on protecting the gut microbiome. Management is ensuring the transparency of European tests, although capitalization remains dependent on equity offerings. The book value per share reflects asset dynamics, where 0.27 determines the current status of the parameter.

Assessing the reliability of equity assets begins with an analysis of net assets, where the calculated value per share is determined as the difference between all company assets and liabilities, divided by the number of shares. For Theriva Biologics, Inc. (TOVX), which depends on oncology R&D results, the current book value per share reflects the actual capital cushion and the efficiency of utilizing grants to cover operating expenses.